

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5388332

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HYDRA BIOSCIENCES, INC.	12/14/2018
RECEIVING PARTY DATA	
Name:	Eli Lilly and Company
Street Address:	Lilly Corporate Center
Internal Address:	Patent Division
City:	Indianapolis
State/Country:	INDIANA
Postal Code:	46285
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11645307
CORRESPONDENCE DATA	
Fax Number:	(317)276-3861
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	patents@lilly.com
Correspondent Name:	ELI LILLY AND COMPANY
Address Line 1:	P. O. BOX 6288
Address Line 2:	PATENT DIVISION
Address Line 4:	INDIANAPOLIS, INDIANA 46206-6288
ATTORNEY DOCKET NUMBER:	X22289
NAME OF SUBMITTER:	PATRICIA A FOOR
SIGNATURE:	/Patricia A Foor/
DATE SIGNED:	02/22/2019
Total Attachments: 5	
source=Patent Assignment Agreement Hydra#page1.tif	
source=Patent Assignment Agreement Hydra#page2.tif	
source=Patent Assignment Agreement Hydra#page3.tif	
source=Patent Assignment Agreement Hydra#page4.tif	
source=Patent Assignment Agreement Hydra#page5.tif	

PATENT ASSIGNMENT AGREEMENT

This PATENT ASSIGNMENT AGREEMENT (the "*Agreement*") is made and effective as of December 14, 2018, by and between Hydra Biosciences, Inc., a Delaware corporation ("*Seller*"), and Eli Lilly and Company, an Indiana corporation ("*Buyer*").

WHEREAS, Seller is an owner of the patents, patent applications, patent disclosures and related patent rights listed on **Schedule 1** (collectively, the "*Patents*"); and

WHEREAS, Seller desires to sell, and Buyer desires to acquire, all of Seller's right, title and interest in and to the Patents pursuant to that certain Asset Purchase Agreement by and among Seller and Buyer dated as of the date hereof (the "*Asset Purchase Agreement*").

NOW, THEREFORE, in consideration of entering into the Asset Purchase Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller hereby sells, assigns, set overs and transfers to Buyer, its successors and assigns all of Seller's entire rights, title and interests in and to the Patents, and agrees to sell, assign, set over and transfer to Buyer, its successors and assigns all of Seller's entire right, title and interest in and to the Patents that are completed or come into existence hereafter, including any non-provisionals, continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof, and any and all patents of the United States and foreign countries that may issue therefrom, and all rights of priority resulting from the filing in the United States of the Patents, and any and all applications for patent and patents issuing therefrom in any and all countries of the world, including all non-provisionals, continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof, and all rights of priority resulting from the filing in the United States of the respective applications for said Patents identified above, the same to be held and enjoyed by Buyer for its own use and enjoyment, and for the use and enjoyment of its successors, assigns and other legal representatives, to the end of the term or terms for which the Patents are or may be granted or reissued as fully and entirely as the same would have been held and enjoyed by the Seller if this Agreement and sale had not been made; together with all claims for damages by reason of past infringements of the Patents including without limitation provisional rights thereto with the right to sue for and collect the same for its own use and benefit, and for the use and on behalf of its successors, assigns and other legal representatives.

Seller agrees that, on request it will sign all lawful papers in connection with all Patents and, with respect thereto, all non-provisionals, continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof, and any and all patents of the United States and foreign countries that may issue therefrom, make all rightful oaths and generally do everything reasonably requested by Buyer to aid Buyer, its successors, assigns and nominees to obtain, maintain, and enforce patent protection in any country for the inventions set forth in the Patents.

In the event of any conflict between this Agreement and the Asset Purchase Agreement, the Asset Purchase Agreement shall control. Nothing in this Agreement shall be deemed to amend or modify in any way any of the terms and conditions of the Asset Purchase Agreement or any rights or obligations of the parties thereto.

IN WITNESS WHEREOF, the undersigned has caused this Patent Assignment Agreement to be executed and delivered as of the date first above written.

BUYER:

ELI LILLY AND COMPANY

By: 

Name: David A. Ricks

Title: President and Chief Executive Officer

SELLER:

HYDRA BIOSCIENCES, INC.

By: _____

Name: Russell Herndon

Title: President and Chief Executive Officer

[Signature Page for Patent Assignment Agreement]

PATENT
REEL: 048407 FRAME: 0957

IN WITNESS WHEREOF, the undersigned has caused this Patent Assignment Agreement to be executed and delivered as of the date first above written.

BUYER:

ELI LILLY AND COMPANY

By: _____
Name: David A. Ricks
Title: President and Chief Executive Officer

SELLER:

HYDRA BIOSCIENCES, INC.

By:  _____
Name: Russell Herndon
Title: President and Chief Executive Officer

[Signature Page for Patent Assignment Agreement]

SCHEDULE 1

See attached.

Attachment to Schedule 1

Application Number	Country	Application Status	Filing Date	Pub Number	Patent Number	Issue Date	App Title
300926493	AU	Granted	23-Jun-2009		200926493	18-Jun-2015	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
2015202546	AU	Granted	23-Jun-2009		2015202546	15-Jun-2017	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
2011203706	AU	Pending	23-Jun-2008				METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	DE	Granted	23-Jun-2008	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
2657468	CA	Granted	23-Jun-2008	2691466	2691466	05-May-2017	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
2962043	CA	Published	23-Jun-2009	2962043			METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	CH	Granted	23-Jun-2009	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
200980103802.8	CN	Granted	23-Jun-2009	101891362	ZL20088103802.8	22-Jan-2014	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
201310719872.7	CN	Granted	23-Jun-2009	CN103751194	ZL201310719872.7	05-Jan-2018	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
201510111689.3	CN	Published	23-Jun-2009	104825427			METHODS AND COMPOSITIONS FOR TREATING DISORDERS
20111272327.4	CN	Published	23-Jun-2008	CN108042542A			METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	DE	Granted	23-Jun-2008	2170309	902000347054.4	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	DK	Granted	23-Jun-2008	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	EP	Granted	23-Jun-2008	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
16195619.0	EP	Published	23-Jun-2009	3184527			METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	ES	Granted	23-Jun-2009	2170309	E08771748	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	FI	Granted	23-Jun-2008	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	FR	Granted	23-Jun-2008	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	GB	Granted	23-Jun-2008	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
10109110.4	HK	Granted	23-Jun-2008	1142541A	HK1142541	12-Jan-2018	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
17133631.6	HK	Pending	23-Jun-2008				METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	IE	Granted	23-Jun-2008	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
4529DELNP2009	IN	Granted	23-Jun-2009		294564	20-Mar-2019	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	IT	Granted	23-Jun-2008	2170309	S020170509034.4	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
3014-109645	JP	Granted	23-Jun-2009		5952983	13-May-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
2015-139797	JP	Granted	23-Jun-2008		6258268	15-Dec-2017	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
2011-131268	JP	Published	23-Jun-2008	2011-165790			METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	NL	Granted	23-Jun-2008	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	NO	Granted	23-Jun-2008	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
08711748.4	SE	Granted	23-Jun-2008	2170309	2170309	26-Oct-2016	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
12744354	US	Granted	23-Jun-2009	US 2009-0143377-A1	8183761	24-Apr-2012	METHODS AND COMPOSITIONS FOR TREATING DISORDERS
15635776	US	Published	30-Jun-2017	US 2018-0133170-A1			METHODS AND COMPOSITIONS FOR TREATING DISORDERS
2013202367	AU	Granted	22-Dec-2006		2013202367	05-Jan-2017	TRPA1 INHIBITORS FOR TREATING PAIN
2016273886	AU	Allowed	22-Dec-2006				TRPA1 INHIBITORS FOR TREATING PAIN
2634182	CA	Published	22-Dec-2006	2634182			TRPA1 INHIBITORS FOR TREATING PAIN
06648704.0	CH	Granted	22-Dec-2006	1962855	1962855	21-Aug-2013	TRPA1 INHIBITORS FOR TREATING PAIN
20098053268.5	CN	Granted	22-Dec-2006	101384281A	ZL20058953268.5	07-Dec-2011	TRPA1 INHIBITORS FOR TREATING PAIN
06848704.0	DE	Granted	22-Dec-2006	1962855	562096338049.6	21-Aug-2013	TRPA1 INHIBITORS FOR TREATING PAIN
00848704.0	ES	Granted	22-Dec-2006	1962855	1962855	21-Aug-2013	TRPA1 INHIBITORS FOR TREATING PAIN
00848704.0	FR	Granted	22-Dec-2006	1962855	1962855	21-Aug-2013	TRPA1 INHIBITORS FOR TREATING PAIN
06848704.0	GB	Granted	22-Dec-2006	1962855	1962855	21-Aug-2013	TRPA1 INHIBITORS FOR TREATING PAIN
09109628.3	HK	Granted	22-Dec-2006	1127736A	1127736	28-Mar-2014	TRPA1 INHIBITORS FOR TREATING PAIN
5412DELNP2009	IN	Published	22-Dec-2006				TRPA1 INHIBITORS FOR TREATING PAIN
06648704.0	IT	Granted	22-Dec-2006	1962855	1962855	21-Aug-2013	TRPA1 INHIBITORS FOR TREATING PAIN
2009-547657	JP	Granted	22-Dec-2006		5859567	25-Dec-2015	TRPA1 INHIBITORS FOR TREATING PAIN
2015-315449	JP	Pending	22-Dec-2006				TRPA1 INHIBITORS FOR TREATING PAIN
2017-145130	JP	Published	22-Dec-2006	2017-200963			TRPA1 INHIBITORS FOR TREATING PAIN
915183257	TW	Granted	22-Dec-2006	422819	422819	21-Jan-2014	COMPOUNDS FOR MODULATING TRPA1 FUNCTION
102135287	TW	Granted	22-Dec-2006	619684	619684	11-Jan-2018	COMPOUNDS FOR MODULATING TRPA1 FUNCTION
105108423	TW	Allowed	22-Dec-2006	201627749			COMPOUNDS FOR MODULATING TRPA1 FUNCTION
10753532	TW	Pending	22-Dec-2006				COMPOUNDS FOR MODULATING TRPA1 FUNCTION
11864507	US	Granted	22-Dec-2006	0219222A1	7671061 B2	02-Mar-2010	METHODS AND COMPOSITIONS FOR TREATING PAIN
12722467	US	Granted	31-Mar-2010	US 2011-0069430-A1	8389529	05-Mar-2013	METHODS AND COMPOSITIONS FOR TREATING ASTHMA
13344233	US	Granted	31-Apr-2012	US 2013-0163283-A1	8641423	24-Sep-2013	METHODS AND COMPOSITIONS FOR TREATING PAIN
13966546	US	Granted	14-Aug-2013	US 2014-0221491-A1	9615639	14-Nov-2017	METHODS AND COMPOSITIONS FOR TREATING PAIN
15785510	US	Published	13-Oct-2017	US 2018-0053986-A1			METHODS AND COMPOSITIONS FOR TREATING PAIN
12680241	US	Granted	15-Jan-2010	US 2010-0261759-A1	8178542	15-May-2012	METHODS AND COMPOSITIONS FOR TREATING PAIN
13661812	US	Granted	26-Oct-2012	US 2013-0303521-A1	8951073	24-Apr-2018	COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES
16922402	US	Published	15-Mar-2018	US 2018-0265511-A1			COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES
13120891	US	Published	24-Sep-2009	US 2012-0046306-A1			METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS
12644108	US	Granted	22-Dec-2009	US 2010-0248154-A1	8262025	29-Jan-2012	COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1
13735604	US	Granted	08-Jan-2013	US 2014-0095208-A1	9005207	14-Apr-2015	COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1
146417176	US	Granted	09-Mar-2015	US 2016-0036495-A1	9649315	16-May-2017	COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1
12696519	US	Granted	29-Jan-2010		9530467	16-Sep-2013	COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1
13061889	US	Granted	12-Apr-2013		9952023	16-Feb-2015	COMPOUNDS USEFUL FOR TREATING INJURIES FROM WARFARE AGENTS
13963586	US	Granted	09-Aug-2013		9012465	21-Apr-2015	COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1
14616160	US	Granted	05-Feb-2015	US 2016-0069709-A1	9505756	29-Nov-2016	COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1
13593772	US	Published	24-Aug-2012	US 2013-0165427-A1			COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES
12465197	US	Granted	14-May-2009	US 2012-0108613-A1	8318728	27-Nov-2012	COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES
13665236	US	Granted	18-Oct-2012	US 2013-0165454-A1	8710052	25-Apr-2014	COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES
147180290	US	Granted	05-Mar-2014	US 2014-0303192-A1	9250431	15-Feb-2016	COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES
14990900	US	Granted	06-Jan-2016	US 2016-0354379-A1	9680969	29-May-2018	COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES
15964653	US	Published	27-Apr-2018	US 2018-0311248-A1			COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES
13702488	US	Granted	08-Jun-2011	US 2013-0310345-A1	8269430	16-Feb-2016	USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL WARFARE AGENTS
14990455	US	Published	07-Jan-2016	2017-0151248			USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL WARFARE AGENTS
20150101221	AR	Published	23-Apr-2015	0100765			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
2015252097	AU	Pending	23-Apr-2015				INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
2945795	CA	Published	23-Apr-2015	2945795			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
20156022160.5	CN	Published	23-Apr-2015	CN106573934A			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
15722319.5	EP	Published	23-Apr-2015	1514410			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
1710867.6	HK	Published	23-Apr-2015	1237333			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
1719279.7	HK	Published	23-Apr-2015	1236524A			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
201617032966	IN	Pending	23-Apr-2015				INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
2016-562799	JP	Pending	23-Apr-2015				INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
104112631	TW	Published	22-Apr-2015	201625618			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
15940253	US	Published	28-Mar-2018	US 2018-0230149-A1			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
003276-2016	VE	Published	23-Apr-2015				INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
20151317337	AU	Pending	18-Sep-2015				INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
2937412	CA	Published	18-Sep-2015	2961412			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
201590050404.4	CN	Published	18-Sep-2015	CN196715430A			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
15774805.2	EP	Published	18-Sep-2015	3193880			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
18180793.9	HK	Pending	18-Sep-2015				INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
20171697213	IN	Published	18-Sep-2015				INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
2017-4515082	JP	Published	18-Sep-2016	2017-528490			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
104131124	TW	Published	21-Sep-2015	201625619			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
159512713	US	Allowed	18-Sep-2015	US 2017-0275295-A1			INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
62780969	US	Pending	14-Nov-2018				INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
62341516	US	Pending	12-Mar-2018				INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL
62524076	US	Pending	21-Jan-2018				INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A3 ION CHANNEL